Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open Label Study of SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Next Previous
Trial Profile

A Phase 1/2 Open Label Study of SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 15 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Pomalidomide (Primary) ; Tagraxofusp (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Stemline Therapeutics

    • Most Recent Events

    • 13 Jan 2022 Status changed from completed to discontinued.
    • 14 Dec 2021 Early results of translational correlative studies using bone marrow (BM), peripheral blood (PB), and serum from this study cohort presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 08 Dec 2020 Initial results of correlative science studies using bone marrow (BM), peripheral blood (PB), and serum from this study cohort (n=9), were presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top